Roche's solid 1st-qtr sales performance beats forecasts

19 April 2016
roche-big

Swiss pharma giant Roche (ROG: SIX) this morning released first-quarter 2016 sales figures, showing that group revenues rose 4% to 12.41 billion Swiss francs ($12.88 billion), a rise of 5% in franc terms, and were better than consensus forecasts of 12.28 billion francs.

Sales of the pharmaceutical business were 9.80 billion francs, up 4% (+5% in SF), while revenues for the company’s Diagnostics division were 2.61 billion francs, a rise of 5% (+4% in SF). Roche, the world’s largest producer of cancer drugs, does not report earnings on a quarterly basis.

Sales in the Pharmaceuticals Division were up 4% to 9.8 billion francs with Europe growing 5%, driven by Perjeta (pertuzumab), MabThera/Rituxan (rituximab) and RoActemra (tocilizumab), first-quarter revenues of which came in at 439 million francs (+33%), 1.83 billion francs (+3%) and 386 million francs (+14%), respectively. Two other major sellers for Roche, Herceptin (trastuzumab) and Avastin (bevacizumab), posted revenues of 1.73 billion francs, up 4%, and 1.71 billion, also up 4%, respectively.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical